BioRestorative Therapies
BRTX
14 hedge funds and large institutions have $502K invested in BioRestorative Therapies in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 1 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
24% more capital invested
Capital invested by funds: $406K → $502K (+$96.2K)
0.02% less ownership
Funds ownership: 4.1% → 4.07% (-0.02%)
7% less funds holding
Funds holding: 15 → 14 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$20.1K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.1K |
| 5 |
SG
StoneX Group
New York
|
+$2.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$30.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15.2K |
BRTX Hedge Fund Activity: Q1 2025 in Review
14 of the 7,466 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q1 2025, worth a combined $502K — up 24% from $406K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BRTX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $20.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $30.7K sold.
- 14 institutional investors held BioRestorative Therapies (BRTX) as of Q1 2025, down from 15 in Q4 2024.
- Funds reported $502K of BioRestorative Therapies stock for Q1 2025, up 24% quarter-over-quarter.
- 0 funds opened new BioRestorative Therapies positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest BioRestorative Therapies buyer in Q1 2025 was Morgan Stanley, an estimated $20.1K added.
- The largest BioRestorative Therapies seller in Q1 2025 was Citadel Advisors, an estimated $30.7K sold.
Based on aggregated 13F filings for Q1 2025.